Atopic Dermatitis Drugs Market Trends, Share, Size, Analysis 2019-2027

| April 15, 2019

article image
According to a new market research report launched by Inkwood Research, the Global Atopic dermatitis was valued nearly $4930 million in 2018 and is anticipated to reach $ 7770 million by 2026, growing at an estimated CAGR of 4.77% during the forecast period of 2019-2027. Browse 24 market data tables and 17 figures spread over 150 pages along with in-depth analysis on Global atopic dermatitis market by Route of Administration (ROA) (Topical, Oral, Injectable) by Drug Class (Topical Antibiotics, Topical Antihistamines, Topical Corticosteroids, Topical Moisturizers/emollients, Topical Calcineurin Inhibitors, Immunomodulators, Off-label Therapies, Systemic Agents, Pde-4 Inhibitor, Interleukin Inhibitor) by Geography

Spotlight

Drug Discovery World

Welcome to our LinkedIn page. This is where we will share articles from our lastest issues, as well as news and other company updates. Now in its 18th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim.’Turning Science into Business’.

OTHER ARTICLES

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | April 6, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | April 6, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | April 6, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Drug Discovery World

Welcome to our LinkedIn page. This is where we will share articles from our lastest issues, as well as news and other company updates. Now in its 18th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim.’Turning Science into Business’.

Events